ImmuneSensor Therapeutics has unparalleled ability in drugging the cGAS/STING pathway to create novel therapeutics for patients with inflammatory and autoimmune diseases
About Us
ImmuneSensor Therapeutics is a clinical-stage biotechnology company focused on developing novel medicines that target the cGAS-STING pathway to modulate the innate immune system. Based on groundbreaking discoveries from the research of the 2024 Lasker Basic Medical Research Award winner, Dr. Zhijian “James” Chen, we are pioneering a differentiated approach with best-in-class cGAS inhibitors to suppress inflammation and autoimmunity when the immune system is overactive.
ImmuneSensor
cGAS-STING Pathway
Discovery of cGAS – the cytoplasmic DNA-sensing enzyme ‐ and its secondary messenger cGAMP ‐ by Dr. Chen's laboratory in 2012 has revolutionized research and drug development efforts into the role of the cGAS-STING pathway in innate immunity and disease. The broad applicability of the pathway in diverse therapeutic areas is now widely recognized to play a critical role in activating innate immune defense triggered by cytosolic DNA from pathogens, cellular stress and damaged tumor cells.
At ImmuneSensor we are leveraging our collective deep knowledge of this critical central pathway in the progression of diverse diseases to develop best-in-class cGAS inhibitors for the treatment of a range of inflammatory and autoimmune diseases.